Natixis Advisors LLC Boosts Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Natixis Advisors LLC boosted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 8.2% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 46,445 shares of the medical equipment provider’s stock after buying an additional 3,516 shares during the quarter. Natixis Advisors LLC’s holdings in Lantheus were worth $5,097,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Signaturefd LLC lifted its position in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares during the last quarter. Silverberg Bernstein Capital Management LLC lifted its position in shares of Lantheus by 0.4% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock worth $1,834,000 after purchasing an additional 100 shares during the last quarter. UMB Bank n.a. lifted its position in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 146 shares during the last quarter. Finally, Moody National Bank Trust Division lifted its position in shares of Lantheus by 1.1% during the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock worth $1,203,000 after purchasing an additional 162 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LNTH has been the subject of several research analyst reports. Truist Financial reiterated a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. JMP Securities decreased their target price on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research report on Thursday, November 7th. Redburn Atlantic started coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective for the company. Finally, StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Thursday. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and an average price target of $122.50.

Lantheus Stock Performance

Shares of Lantheus stock opened at $90.52 on Friday. The company has a market capitalization of $6.29 billion, a PE ratio of 15.06 and a beta of 0.51. The company has a 50-day simple moving average of $103.43 and a two-hundred day simple moving average of $96.53. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.